Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including excessive daytime sleepiness, sleep inertia and prolonged sleep duration with
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity.
ODE for IH for adults follows June 2021 grant of ODE for treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy DUBLIN, Jan. 3, 2022 /PRNewswire/
Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.